Best Biopharma Outsourcing Companies in China
The 377 best Biopharma Outsourcing companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Ausco Biopharma.
China's Biopharma Outsourcing sector is moving fast, and this directory ranks 377 companies operating across it, ordered by disclosed equity funding and recent momentum. Total disclosed funding sits at $5.2B, spread across a field where VelaVigo leads at $160M raised, Jiangsu Vcare Pharmatech follows at $107M, and Zhejiang Mingdu Zhikong Technology has pulled in $73M. No unicorns yet, which tells you something about where the valuation cycle sits, but the capital is clearly accumulating. The global market behind all this stood at roughly $28.7B in 2024 and is forecast to reach $112.3B by 2032, a 5.8% CAGR driven by surging biologics demand and the relentless rise in drug development costs.
So what's the actual texture of the moment? Coverage is expanding and the hot themes right now are clinical trial outsourcing and operational resilience, two areas where China-based CROs and CMOs are increasingly competitive on cost and scale. Regulatory compliance pressure is real and tightening, which tends to consolidate spend toward better-capitalized players. I'd watch how firms like ChemLex ($26M) and Regend Therapeutics ($16M) position against that pressure. Investors like Qiming Venture Partners and Legend Capital are the ones placing those bets. If you're mapping the space, this list is where to start.
- ResearchAndMarkets.com
Our analysis of 100 Biopharma Outsourcing companies
$10.3b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in China
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Ausco Biopharma Developer of recombinant proteins | $407M | 53 mo ago | — | 2017 | Shun Luo Founder & CEO | — | — | — |
| 2 | Pharmaron Suite of drug discovery and development services for small molecules | $320M | 126 mo ago | 476 | 2003 | Larry Lou Co-Founder | WordPress Block EditorWordPressMySQL+23 | — | — |
| 3 | Chime Biologics Provider of contract development and manufacturing services catering to the biopharma sector | $315M | 62 mo ago | 400 | 2013 | James Huang CEO | WordPressMySQLPHP+15 | — | 1 partnership |
| 4 | Luoxin Pharmaceutical Group Developer and manufacturer of pharmaceutical products | $301M | — | 6,000 | 2006 | — | Apple iCloud MailWindows ServerMicrosoft ASP.NET+3 | — | — |
| 5 | ZGBiotech CDMO focused on drug development, analytical, formulation, and quality testing services 72Funding top 24%Market top 28%Global bottom 38% All 3 signals ▾Fundingtop 24% Markettop 28% Globalbottom 38% Funding: Raised $240M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Market: 600 employees (top 9% of Industrial Goods and Manufacturing) rank vs industry peers · Fliar Intelligence Index 72/100 | $240M | 46 mo ago | 600 | 2017 | — | — | — | — |
| 6 | Shandong Xuanzhu Pharmaceutical Technology Developer of therapies for treating cardiovascular diseases, cancer, and diabetes | $210M | 53 mo ago | — | 2002 | Haigui CEO | — | — | — |
| 7 | Shanghai Cell Therapy Group Provider of cell-therapy focused research and development services | $202M | 62 mo ago | 70 | 2014 | — | PHPLayuiTengine+3 | — | — |
| 8 | Novast Laboratories Researches and develops finished products and API formulations | $186M | 73 mo ago | — | 2005 | Prasad Pinnamaraju President | — | 7 patents Advanced solid dosage forms and nitrosamine impurity detection for pharmaceutical products | — |
| 9 | Viva Biotech Research services focused on drug discovery and development | $180M | 36 mo ago | 2,271 | 2006 | — | PHPNginxSwiper+7 | — | — |
| 10 | Innoforce Pharmaceuticals Manufacturer of biopharmaceuticals | $179M | 54 mo ago | 2 | 2018 | Yuling Li Founder & CEO | — | — | — |
| 11 | Jilin Huisheng Bio-Pharmaceutical Provider of drug research, clinical development, marketing, and other services | $160M | 41 mo ago | 200 | 2019 | — | — | — | — |
| 12 | VelaVigo Biotechnology research company developing biological drugs | $160M | 10 mo ago | — | 2021 | Tong Zhang Co-Founder | — | — | 1 job opening |
| 13 | Hangzhou multi Jubilee Biotechnology Provider of drug research and development services | $155M | 61 mo ago | 98 | 2012 | — | — | — | — |
| 14 | Beijing Biostar Technologies Developer and manufacturer of APIs, intermediates, & biochemical reagents | $135M | 66 mo ago | 148 | 2002 | Qiu Rongguo Co-CEO | — | — | — |
| 15 | Arctic Vision Limited information available | $132M | 63 mo ago | 50 | 2019 | Eddy Wu Founder & CEO | — | — | — |
| 16 | MabPlex CDMO offering biologics development and manufacturing services | $130M | 72 mo ago | 667 | 2013 | — | — | 11 patents ADC linker chemistry and conjugation processes for SN‑38 and binary toxin payloads | 1 partnership |
| 17 | Nuokong Biopharma Developer of injectables and APIs | $112M | 164 mo ago | — | 1997 | Xue Baizhong Founder & CEO | — | — | — |
| 18 | Jiangsu Vcare Pharmatech CDMO manufacturing APIs | $107M | 29 mo ago | 500 | 2010 | — | — | 66 patents Small‑molecule kinase and receptor modulators for inflammatory and oncologic therapies | — |
| 19 | HwaGen Pharma CDMO focused on manufacturing of APIs | $100M | 57 mo ago | 500 | 2015 | — | — | — | — |
| 20 | Concordmedical Radiotherapy and diagnostic imaging centers | $100M | 75 mo ago | 893 | 1996 | — | PHPWindows ServerThinkPHP+5 | — | — |
| 21 | OBiO Technology CDMO focused on providing services for cell & gene therapy products | $88M | 68 mo ago | — | 2013 | Oudong Pan Founder | CodeMirrorTinyMCEPHP+13 | — | — |
| 22 | Porton Advanced Solutions Provider of cell & gene therapy, discovery research, analytical development, and testing services | $80M | 45 mo ago | — | 2018 | Yangzhou Wang CEO | WordPressMySQLPHP+18 | — | 1 launch |
| 23 | IntellectiveBio CDMO focused on biopharmaceutical process development | $74M | 46 mo ago | 100 | 2018 | — | — | — | — |
| 24 | Zhejiang Mingdu Zhikong Technology Provider of AI based logistics services | $73M | 27 mo ago | 500 | 2017 | Wang Lijun CEO | — | — | — |
| 25 | Shaanxi Micot Technology Provider of drug research and development services focused on cardiovascular and metabolic diseases | $72M | 60 mo ago | 60 | 2007 | Wang Bing Founder Chairman & President | — | 22 patents Therapeutic peptide biopharma targeting anticoagulation, antiplatelet, and immune modulation | — |
| 26 | Qyuns Therapeutics Provider of drug development services to biopharma sector | $66M | 61 mo ago | 313 | 2015 | Jiwan Qui CEO | — | 76 patents Therapeutic monoclonal antibodies against IL‑33, IL‑36R, CD117, and TSLP for inflammatory diseases | — |
| 27 | Fountain Medical Development Full-service CRO based out of China and East Asia | $62M | 79 mo ago | 66 | 1995 | Ling Zhen CEO & Co-Chairman | — | — | — |
| 28 | Suzhou Ze Jing Biological Pharmaceutical Company developing small molecules & eukaryotic cell based recombinant protein drugs | $62M | 101 mo ago | 843 | 2009 | — | — | — | — |
| 29 | MabSpace Biosciences Platform for antibody discovery and development | $55M | 97 mo ago | 60 | 2013 | — | — | 10 patents Therapeutic antibodies against claudin‑18.2 and PD‑L1 for cancer treatment | — |
| 30 | Raynovent Provider of marketing services | $54M | 41 mo ago | — | 2018 | Chaofeng Long Co-Founder | — | — | — |
| 31 | Bellen Chemistry Research and manufacturing of API and intermediates, while specializing in heterocycles | $53M | 71 mo ago | 1,000 | 2007 | — | — | — | — |
| 32 | Yiming Provider of research and cell & gene therapy development services | $49M | 57 mo ago | — | 2015 | — | — | 136 patents Patents concentrated in electrical & electronics | — |
| 33 | Nexchem Pharmaceutical Company engaged in manufacturing APIs | $45M | 181 mo ago | 250 | 2002 | — | — | — | — |
| 34 | Canton Biologics CDMO focused on manufacturing of cell based therapy products | $41M | 33 mo ago | 100 | 2016 | — | — | 17 patents Recombinant protein expression and bispecific antibody manufacturing technologies | — |
| 35 | Eccogene CRO focused on development of drugs for metabolic and immune-related diseases | $40M | 36 mo ago | — | 2018 | Jingye Zhou Co-Founder & CEO | — | 3 patents SSAO enzyme inhibitors—heterocyclic small‑molecule pharmaceuticals targeting amine oxidase activity | — |
| 36 | WuXi AppTec Provider of CRO and CDMO services | $40M | 62 mo ago | 1,681 | 2000 | — | WordPressMySQLRedis+29 | 20 patents Drug discovery platforms and small‑molecule/biologic modulators for immune and ion channels | — |
| 37 | Anticancer Bioscience Provider of drug discovery and development services for oncology | $31M | 56 mo ago | 50 | 2016 | Dun Yang CEO & President | — | 38 patents Patents concentrated in chemistry & materials | — |
| 38 | Shanghai Bocimed Pharmaceutical Developer and manufacturer of APIs and intermediates | $29M | 40 mo ago | 200 | 2007 | — | — | — | — |
| 39 | CHIGENOVO Biotechnology company focused on developing gene therapy drugs for eye diseases | $26M | 32 mo ago | — | 2016 | Zhong Xiancheng CEO | — | 41 patents AAV‑based gene therapy and editing platforms for inherited retinal dystrophies | — |
| 40 | ChemLex Provider of consulting services in the field of chemical research and development through artificial… | $26M | 6 mo ago | — | — | Sean Lin Founder & CEO | BootstrapGSAPAmazon Web Services+5 | — | — |
| 41 | GENFINE Biotech Manufacturer and supplier of pharmaceutical products | $23M | 64 mo ago | — | 2017 | Yang Liang Founder & CEO | — | — | — |
| 42 | Hangzhou Changxi Provider of inhalation drug delivery platform services to pharma companies | $21M | 72 mo ago | — | 2014 | Huang Peng Co-founder & Vice President | — | — | — |
| 43 | Regend Therapeutics CDMO focused on manufacturing of cell & gene therapy services | $16M | 4 mo ago | — | 2015 | Jimmy Ruisheng Co-Founder | — | 10 patents Autologous cell‑based regenerative therapies for pulmonary fibrosis and kidney regeneration | — |
| 44 | Tianti Biotherapeutics Provider of drug research and development services for pharmaceutical sector | $16M | 53 mo ago | — | — | — | — | — | — |
| 45 | Shanghai Yaocheng Health Technology Provider of clinical trial services to biopharma sector | $15M | 44 mo ago | 100 | 2020 | Xu Pengcheng Co-Founder & CEO | — | — | — |
| 46 | PAM²L Biotechnologies Supplier and wholesaler of bio-pharmaceutical products | $15M | 41 mo ago | — | 2021 | Zhong Chao Founder | — | — | — |
| 47 | Yinjia Biotech Provider of protein reagents, kits, and related products for biopharmaceutical applications | $15M | 41 mo ago | — | 2020 | Wu Yifei Founder & CEO | — | — | — |
| 48 | ICE Bioscience Specialised CRO offering a range of screening platforms for cardiac safety testing, ion channel profiling and… | $14M | 25 mo ago | 19 | 2010 | Li Yan CEO | anime.jsYouTubeNginx+7 | — | — |
| 49 | CarbonSilicon Provider of AI computing solutions for drug research & development services | $7M | 44 mo ago | — | 2022 | Shi Hui Co-Founder | — | — | — |
| 50 | EnsiliTech CDMO focused on antibodies, vaccines, and other therapeutics drugs development services | $1M | 9 mo ago | 7 | 2022 | Asel Sartbaeva CEO | Cart FunctionalitySquarespace CommerceSquarespace+15 | — | 4 awards |
Top 12 Biopharma Outsourcing companies in China
#1
Seed · Shanghai, Shanghai · founded 2021$160Mraised▾
Biotechnology research company developing biological drugs. It is a biopharmaceutical research company that develops biological drugs including bispecific and multi specific antibodies, ADC, and new modalities.
- Jul 2025Seed$60M
- Dec 2024Seed$50M
- Nov 2021Angel$50M
#2
Series C · Suzhou, Jiangsu · founded 2015$15.8Mraised▾
Developer of stem cell therapy products and human organ regenerative medicine. The company is mainly engaged in research and development of regenerative medicine, providing users with interstitial lung disease, assisted reproduction, stem cell storage and chronic obstructive pulmonary disease treatment solutions.
- Feb 2026Series C$50.6M
- Mar 2022Series B$15.8M
#3
Series B · Shanghai, Shanghai$26Mraised▾
ChemLex is a knowledge-based company that focuses on closed-loop collaborative research and development through artificial intelligence chemical synthesis path planning and high-throughput. They offer comprehensive consulting services in the field of chemical legislation and plant protection products.
- Dec 2025Series B$45M
#4
Seed · Shandong · founded 2022 · 7 employees$1.5Mraised▾
CDMO focused on antibodies, vaccines, and other therapeutics drugs development services
- Aug 2025Seed$6M
- Jan 2023Seed$1.5M
#5
Series C · Nanjing, Jiangsu · founded 2010 · 500 employees$107.3Mraised▾
CDMO manufacturing APIs
- Jan 2024Series C$63.3M
- Dec 2022Series B$28.6M
- Jul 2021Series B$15.5M
#6
Series C · Hangzhou, Zhejiang · founded 2017 · 500 employees$73.1Mraised▾
Provider of AI based logistics services
- Feb 2024Series C—
- May 2021Series B$47.1M
- Jul 2020Series A$11.4M
- Jul 2019Series A$14.5M
#7
Public · Shanghai, Shanghai · founded 2006 · 2271 employees$180Mraised▾
Viva is a multidisciplinary CRO with a focus on drug discovery and development. The company's services include Gene-to-protein and Gene-to-structure services, drug discovery with a focus on GPCR targets and antibody therapeutics discovery, fragment-based drug screening, medicinal chemistry, translational and in vivo pharmacology, in vitro pharmacology, DMPK and protein analysis, including crystallography services.
- Jun 2023Post IPO—
- Jan 2020Post IPO$180M
- 2017Series A—
#8
Series D · Nantong, Jiangsu · founded 2017$406.7Mraised▾
Ausco Biopharma develops recombinant proteins. They offer services including process development and production for recombinant protein products such as antibodies and antibody fragments, clotting factor products, and vaccine products such as viral vaccines and bacterial vaccines, viral particle products.
- Jan 2022Series D$235.9M
- Mar 2021Series C$61.4M
- Jul 2020Series B$64.3M
- Jan 2019Series A$45M
#9
Series C · Shanghai, Shanghai · founded 2017 · 600 employees$239.7Mraised▾
CDMO focused on drug development, analytical, formulation, and quality testing services
- Aug 2022Series C$14.7M
- Jan 2022Series C$100M
- Mar 2021Series B$70M
- Mar 2020Series A$51M
#10
Series A · Jilin, Jilin · founded 2019 · 200 employees$160.5Mraised▾
Developer of biopharmaceutical therapeutics intended to better treat diabetes and its complications. The company operates several product R&D pipelines to discover innovative drugs for diabetes treatment, enabling patients to live a quality life.
- Jan 2023Series A$85.6M
- Jun 2022Series A$74.9M
#11
Series C · Guangzhou, Guangdong · founded 2016 · 100 employees$41.2Mraised▾
CDMO focused on manufacturing of cell based therapy products
- Sep 2023Series C$41.2M
- Aug 2016Grant (prize money)$173.1K
- May 2016Grant (prize money)$189.7K
#12
Series B · Jinan, Shandong · founded 2002$209.7Mraised▾
Shandong Xuanzhu Pharmaceutical Technology is a subsidiary of Sihuan Pharmaceutical Holdings. They are developing therapies for treating cardiovascular diseases, cancer, and diabetes. Their lead candidate XZP - 5491 is used to treat cancer. It is an ERBB 2 (epidermal growth factor receptor) receptor, antagonist. Other candidates are mostly in phase I clinical trials. They also offer development services for APIs and intermediates such as process development, scale-up, synthesis, etc.
- Dec 2021Series B$94.1M
- Aug 2020Series A$115.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in China
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 5,865 China-affiliated papers.
- Chinese Academy of Sciences263
- Chinese Academy of Agricultural Sciences227
- Ministry of Agriculture and Rural Affairs168
- China Agricultural University159
- Huazhong Agricultural University138
- Gene4→218
- Gene knockdown3→73
- Transcriptome1→62
- Detection limit1→59
- Mutant3→56
- Gene9→275
- Gene knockdown1→166
- Downregulation and upregulation2→161
- Apoptosis6→129
- Transcription factor3→77
- Agriculture6→68
- Antibiotic resistance1→43
- Resistance (ecology)2→33
- Gene2→32
- Synthetic biology1→30
Where biotechnology is researched across China
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in China
China biotechnology patent filing is accelerating — 58,925 filings from 8,000 assignees (2016–2025), led by Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine, UNIV Jiangnan; annual filings 1737→10545.
- Shanghai Hengrui Pharmaceutical1154
- Jiangsu Hengrui Medicine1027
- UNIV Jiangnan1000
- Innovent Biologics Suzhou666
- UNIV Tsinghua627
- Jiangsu Hengrui Pharmaceuticals594
- UNIV Xiamen575
- UNIV Beijing549
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.